Cytotoxic effects of a recombinant chimeric toxin on rapidly proliferating vascular smooth muscle cells

S E Epstein1, C B Siegall, S Biro

  • 1Cardiology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892.

Circulation
|August 1, 1991
PubMed
Abstract

Insights

This study developed a chimeric toxin, TGF alpha-PE40, that selectively targets and kills rapidly proliferating smooth muscle cells (SMCs) by binding to the epidermal growth factor (EGF) receptor. This approach shows potential for treating conditions like restenosis by eliminating problematic SMCs.

Area of Science:

  • Vascular Biology
  • Molecular Therapeutics
  • Cell Biology

Background:

  • Restenosis after angioplasty involves medial smooth muscle cell (SMC) proliferation, migration, and lumen narrowing.
  • Cancer cells are targeted using cytotoxic agents due to increased cell surface receptors.
  • Pseudomonas exotoxin (PE) is a potent cell toxin; PE40 is a modified version with reduced toxicity.

Purpose of the Study:

  • To investigate if a chimeric toxin can selectively target and eliminate rapidly proliferating SMCs, similar to cancer cell targeting.
  • To assess the efficacy of a novel TGF alpha-PE40 toxin against proliferating SMCs.

Main Methods:

  • A chimeric toxin, TGF alpha-PE40, was constructed by linking complementary DNA for transforming growth factor alpha (TGF alpha) and PE40.
  • Escherichia coli was used to express the TGF alpha-PE40 toxin.
  • The cytotoxic effects of TGF alpha-PE40 on SMCs were evaluated in vitro under conditions promoting proliferation (low cell density, 10% FBS) versus quiescence (0.5% FBS).

Main Results:

  • TGF alpha-PE40 demonstrated high cytotoxicity against rapidly proliferating SMCs (ID50, 4.0 ng/ml).
  • Cytotoxicity was significantly reduced (30-fold less) against quiescent SMCs (ID50, 125 ng/ml).
  • Competition studies confirmed that TGF alpha-PE40's effects are specifically mediated by the epidermal growth factor (EGF) receptor.

Conclusions:

  • Rapidly proliferating SMCs express 10-fold more EGF receptors than quiescent SMCs in vitro.
  • The chimeric toxin TGF alpha-PE40 selectively kills rapidly proliferating SMCs via EGF receptor targeting.
  • Further in vivo studies are needed to determine the therapeutic potential of this toxin for preventing restenosis.

Related Concept Videos

Classification of Skeletal Muscle Relaxants01:28

Classification of Skeletal Muscle Relaxants

Skeletal muscle relaxants are a group of drugs that can reduce muscle stiffness and induce temporary paralysis to relieve pain. These agents can act centrally to reduce muscle tone or spasms in painful conditions such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), or spinal injuries; they are called antispasmodics or spasmolytics.
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
Depolarizing Blockers: Mechanism of Action01:28

Depolarizing Blockers: Mechanism of Action

Depolarizing blockers act on skeletal muscle fibers' membranes and induce their depolarization. Most depolarizing blockers have two quaternary N+ atoms that bind the nicotinic acetylcholine receptors and cause neuromuscular blockade within minutes.
Succinylcholine is the most commonly used depolarizing blocker. Chemically, it constitutes two molecules of acetylcholine joined together by an acetate methyl group. They act on the receptors in the same way as acetylcholine. Because succinylcholine...
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin01:26

Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin

Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
Skeletal Muscle Relaxants: Adverse Effects01:21

Skeletal Muscle Relaxants: Adverse Effects

Skeletal muscle relaxants are widely used for muscle paralysis and relieving pain following any muscle injury or stiffness. However, depending on the drug type, they can have adverse effects that range from mild to severe. Usually, nondepolarizing neuromuscular blockers have minimal side effects. For example, drugs like d-tubocurarine, cisatracurium, and rocuronium cause hypotension, whereas drugs like baclofen, when stopped abruptly, can lead to the recurrence of spastic conditions.
Unlike...
Skeletal Muscle Relaxants: Therapeutic Uses01:31

Skeletal Muscle Relaxants: Therapeutic Uses

Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx as...
Botulism01:22

Botulism

Botulism is a life-threatening neuroparalytic condition caused by botulinum neurotoxin, which is produced by the bacterium Clostridium botulinum, a Gram-positive, spore-forming, obligate anaerobe.In adults, the toxin enters the body in different ways: in foodborne botulism, the preformed toxin is absorbed in the intestine. In wound botulism, spores grow in injured tissue and release the toxin into the blood. Infant botulism differs mechanistically from adult forms. In infants, botulism commonly...